Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financial Conflict In Trials Should Be Ignored In Complex Cases – AdvaMed

This article was originally published in The Gray Sheet

Executive Summary

Medical technology inventors should be permitted to participate as clinical trial investigators provided their interests are disclosed beforehand, AdvaMed claims in comments to an HHS proposal regulating financial conflict of interests in medical studies

You may also be interested in...



Industry/Academic Research CoI Guidelines Urged By Beckman Coulter CEO

Voluntary guidelines stipulating conflicts of interest between medical product manufacturers and academic facilities pursuing joint R&D should include a certification and inspection component, Beckman Coulter CEO John Wareham suggested Oct. 7

Industry/Academic Research CoI Guidelines Urged By Beckman Coulter CEO

Voluntary guidelines stipulating conflicts of interest between medical product manufacturers and academic facilities pursuing joint R&D should include a certification and inspection component, Beckman Coulter CEO John Wareham suggested Oct. 7

Regulatory News In Brief

HHS issues conflict of interest draft guidance: "1Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection" recommends taking measures such as separating responsibility for financial and research decisions and establishing CoI committees to verify the absence of financial interests. Aimed at individuals and organizations engaged in human subjects research, the March 31 guidance provides points to consider and aligns with December 2001 GAO recommendations calling on HHS to develop best practices for managing investigator and institutional financial CoI in biomedical research. Comments on the guidance are due by May 30...

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel